Trophoblast cell surface antigen-2 (Trop-2) is a 35-kDa transmembrane glycoprotein and calcium signal transducer encoded by the TACSTD2 gene, and is structurally related to epithelial cell adhesion molecule (EpCAM).
Global TROP2 Antibody Market Clinical Trials Insight 2026 Report Findings:
- Research Methodology
- Global & Regional Market Analysis
- Global TROP2 Antibody Market Opportunity Assessment
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 1 Drugs
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report
Trophoblast cell surface antigen-2 (Trop-2) is a 35-kDa transmembrane glycoprotein and calcium signal transducer encoded by the TACSTD2 gene, and is structurally related to epithelial cell adhesion molecule (EpCAM). The gene is expressed in normal human tissues, including breast, cervix, kidney, lung and pancreas, and participates in embryonic development. Further, it is shown that it is upregulated in several cancers such as head and neck squamous cell carcinoma, gastric cancer, gallbladder cancer, cervical cancer, lung cancer, breast cancer, colon cancer, pancreatic cancer, ovarian carcinoma, endometrioid endometrial carcinoma. Therefore, it is believed that drugs that can tackle Trop-2 could potentially treat many cancers with unmet need.
The robust research and development activities have led to development of several Trop-2 targeting approaches including monoclonal antibodies, chimeric antigen receptor T-cell therapy, and small molecule inhibitor. At present, no small molecule inhibitor is present in development because of complexity of the function of the Trop 2 protein as well as the compensatory role of Trop 2 in oncogenesis. Apart from this, antibodies targeting TROP2 have shown limited efficacy. To overcome this, researchers have conjugated the monoclonal antibody with cytotoxic agent to enhance their efficiency. Till date, antibody drug conjugate represents the most promising class for targeting TROP2.
Trodelvy (Sacituzumab govitecan) is a first-in-class antibody and topoisomerase inhibitor conjugate directed to the Trop-2 receptor developed by Immunomedics. It is a novel antibody drug conjugate composed of an anti-Trop-2 humanized monoclonal antibody hRS7 IgG1κ coupled to the payload SN-38, an active metabolite of irinotecan, a topoisomerase I inhibitor. The drug is approved for the management of triple negative breast cancer in multiple countries worldwide, including Australia, Canada, UK, the European Union, Switzerland and US. Apart from this, US FA has also approved the drug for the management of metastatic urothelial cancer.
The introduction of Trodelvy in the global market has shown high penetration in the global market as it is first TROP2 targeting drug as well as targeted drug for the management of triple negative breast cancer (TNBC). The drug Trodelvy continues to be developed for potential use in other TNBC populations and is also being developed as an investigational treatment for hormone receptor positive/human epidermal growth factor receptor-2 negative metastatic breast cancer and non-small cell lung cancer. Additional evaluation across multiple solid tumors is also underway. Apart from this, several combinational trials are also ongoing which aim to enhance the efficacy of the drug. For instance, Trodelvy is being evaluated in combination with Keytruda as first-line treatment for advanced or metastatic TNBC.
The accelerated approval of Trodelvy and its robust response in the market has encouraged several pharmaceutical giants to actively indulge in the development of novel TROP2 targeting drugs. The pipeline for TROP2 inhibitors is highly crowded and consists of several candidates including DS-1062a, RN927C, BAT8003, SKB264, JS108, and several others which are designed to target a wide range of cancers including non-small cell lung cancer, epithelial cancer, skin cancer, colon cancer, and others. As per our analysis, the coming years will see several product launches which will boost the growth of global TROP2 inhibiting drugs market.
The report, Global TROP2 inhibitors estimates that the market will surpass US$ XX Million by 2026. The report provides comprehensive analysis on the currently marketed drug along with emerging drugs in development. On the basis of therapeutic indication, the market is segmented into breast, urothelial, lung, prostate, and pancreatic cancer. On the basis of region, the market is segmented into Japan, US, Europe, and rest of world. The report also provides information on the competitive landscape. The major companies mentioned in report are Arius Research, Janux Theray, Immunomedics, Pfizer, Daiichi Sankyo, Gilead Science, and AstraZeneca.
Contact:
Neeraj Chawla
Research head
Kuick Research
+91-9810410366